By Bill Bergfeld
Studies recently completed at the University of Texas Southwestern Medical Center by a research team led by Dr. Jay Horton point to the possibility of using antibodies to lower the circulating LDL Cholesterol levels.
They identified a protein believed to possess the capability of harmfully blocking the removal of LDL (low-density lipoprotein) from circulation. Using an extremely simplified explanation, these proteins block the body's ability to filter LDL from the blood by clogging the specifically designed LDL receptor holes in the screen.
The antibodies, according to their research, have the ability to prevent these proteins from plugging the holes in the filtering screen.
While statin medications increase the number of holes in the screen (LDL receptor cells), an added benefit could be realized if those holes already present were made immune to blockage. "These studies suggest that inhibiting PDSK9's (the harmful protein) action may be another route to lowering LDL cholesterol in individuals with high cholesterol," said Dr. Horton.
Further information can be found in Proceedings of the National Academy of Sciences.
